Gilead Sciences, Inc. GILD
NASDAQ · Healthcare · Drug Manufacturers - General
$166.43
Close on Fri, 20 Nov 2026 · market value $206B
What the price is betting on
Below its recordAt $166, the price assumes revenue shrinks about 5.5% a year for five years, from $31B to about $24.4B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.9% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than GILD? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$283
Base
$323
Bull
$369
Today $166
- Bear $283. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $323. Cash flow grows 6% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $369. Cash flow grows 8% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$30.6B$31.3B, on the path
- FY2027$28.9B$33.6B, on the path
- FY2028$27.3B$34.7B, on the path
- FY2029$25.8B$37.3B, on the path
- FY2030$24.4B$39.6B, on the path
Each year's revenue at −5.5% growth from $31B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NASDAQ
- Revenue, FY2025
- $29.4B
- Growth, 3 years a year
- 5%
- Cash margin
- 32%
- Net debt
- $15.3B
- Shares, 3-year change
- −0.6%
- Dividend yield
- 1.9%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.